Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 5/2020

01-05-2020 | Lung Cancer | Original Article

Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma

Authors: Naoki Ozeki, Koji Kawaguchi, Takayuki Fukui, Shota Nakamura, Shuhei Hakiri, Shunsuke Mori, Masaki Goto, Shingo Iwano, Kohei Yokoi, Toyofumi Fengshi Chen-Yoshikawa

Published in: International Journal of Clinical Oncology | Issue 5/2020

Login to get access

Abstract

Background

Psoas muscle mass is a surrogate marker for sarcopenia: a depletion of skeletal muscle mass. This study was conducted to elucidate the prognostic significance of the psoas muscle index (PMI: cross-sectional area of the bilateral psoas muscle at the umbilical level on computed tomography/height2 [cm2/m2]) in patients undergoing surgery for lung squamous cell carcinoma (SCC) and lung adenocarcinoma (ADC).

Methods

One hundred and sixty-five patients with SCC and 556 patients with ADC who underwent R0 resection between 2007 and 2014 were reviewed for analysis. In SCC patients, the mean value (standard deviation) of the PMI was 6.15 (1.49) in men and 4.65 (1.36) in women. Among ADC patients, the PMI was 7.12 (1.60) in men and 5.29 (1.22) in women. Clinicopathological characteristics as well as the survival were evaluated.

Results

The PMI was associated with the age, body mass index (BMI), and serum albumin. In the multivariable Cox regression analysis, after adjusting for age, BMI, serum albumin, sex, pathological stage, and diffusing capacity for carbon monoxide, the PMI showed a significant association with the overall survival (OS) and disease-free survival (DFS) in SCC patients (hazard ratios 0.50 and 0.56, 95% confidence intervals 0.39–0.65 and 0.45–0.71, respectively). On the other hand, in ADC patients, the PMI had no impact on the OS or DFS.

Conclusions

The PMI was significantly associated with the survival of lung SCC patients, but not of lung ADC patients, suggesting the presence of a previously unidentified relationship between skeletal muscle and lung SCC progression.
Literature
1.
2.
Okumura S, Kaido T, Hamaguchi Y et al (2015) Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery 157:1088–1098CrossRefPubMed
3.
Onesti JK, Wright GP, Kenning SE et al (2016) Sarcopenia and survival in patients undergoing pancreatic resection. Pancreatology 16:284–289CrossRefPubMed
4.
Yaguchi Y, Kumata Y, Horikawa M et al (2017) Clinical significance of area of psoas major muscle on computed tomography after gastrectomy in gastric cancer patients. Ann Nutr Metab 71:145–149CrossRefPubMed
5.
Cornet M, Lim C, Salloum C et al (2015) Prognostic value of sarcopenia in liver surgery. J Visc Surg 152:297–304CrossRefPubMed
6.
Smith AB, Deal AM, Yu H et al (2014) Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol 191:1714–1720CrossRefPubMed
7.
Park SY, Yoon JK, Lee SJ et al (2017) Prognostic value of preoperative total psoas muscle area on long-term outcome in surgically treated oesophageal cancer patients. Interact CardioVasc Thorac Surg 24:13–19CrossRefPubMed
8.
Yoshikawa T, Takano M, Miyamoto M et al (2017) Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol 80:555–561CrossRefPubMed
9.
Suzuki Y, Okamoto T, Fujishita T et al (2016) Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. Lung Cancer 101:92–97CrossRefPubMed
10.
Hervochon R, Bobbio A, Guinet C et al (2017) Body mass index and total psoas area affect outcomes in patients undergoing pneumonectomy for cancer. Ann Thorac Surg 103:287–295CrossRefPubMed
11.
Nakamura R, Inage Y, Tobita R et al (2018) Sarcopenia in resected NSCLC: effect on postoperative outcomes. J Thorac Oncol 13:895–903CrossRefPubMed
12.
Sun C, Anraku M, Karasaki T et al (2018) Low truncal muscle area on chest computed tomography: a poor prognostic factor for the cure of early-stage non-small-cell lung cancer. Eur J Cardiothorac Surg 55:414–420CrossRef
13.
Ozeki N, Fukui T, Taniguchi T et al (2014) Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. Eur J Cardiothorac Surg 45:687–692CrossRefPubMed
14.
Brierley JD, Gospodarowicz MK, Wittekind C (2016) TNM classification of malignant tumours, 8th edn. Wiley-Blackwell, New York
15.
Travis WD, Brambilla E, Burke AP et al (2015) WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
16.
Kurokawa T, Matsuno Y, Noguchi M et al (1994) Surgically curable “early” adenocarcinoma in the periphery of the lung. Am J Surg Pathol 18:431–438CrossRefPubMed
17.
Ozeki N, Kawaguchi K, Fukui T et al (2017) The diffusing capacity of the lung for carbon monoxide is associated with the histopathological aggressiveness of lung adenocarcinoma. Eur J Cardiothorac Surg 52:969–974CrossRefPubMed
18.
Ozeki N, Kawaguchi K, Okasaka T et al (2017) Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery. Nagoya J Med Sci 79:37–42PubMedPubMedCentral
19.
Attaran S, McShane J, Whittle I et al (2012) A propensity-matched comparison of survival after lung resection in patients with a high versus low body mass index. Eur J Cardiothorac Surg 42:653–658CrossRefPubMed
20.
Ozeki N, Fukui T, Kawaguchi K et al (2018) A survival analysis using physique-adjusted tumor size of non-small cell lung cancer. Int J Clin Oncol 23:266–274CrossRefPubMed
21.
Miura K, Hamanaka K, Koizumi T et al (2017) Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: comparative study of normal lung, emphysema, and pulmonary fibrosis. Lung Cancer 111:88–95CrossRefPubMed
22.
Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465CrossRefPubMed
23.
Takamori S, Toyokawa G, Okamoto T et al (2018) Clinical impact and risk factors for skeletal muscle loss after complete resection of early non-small cell lung cancer. Ann Surg Oncol 25:1229–1236CrossRefPubMed
Metadata
Title
Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma
Authors
Naoki Ozeki
Koji Kawaguchi
Takayuki Fukui
Shota Nakamura
Shuhei Hakiri
Shunsuke Mori
Masaki Goto
Shingo Iwano
Kohei Yokoi
Toyofumi Fengshi Chen-Yoshikawa
Publication date
01-05-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 5/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01624-x

Other articles of this Issue 5/2020

International Journal of Clinical Oncology 5/2020 Go to the issue

Original Article

Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis

Editorial

A message from the new editor-in-chief

Original Article

Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma

Original Article

Laparoscopic versus abdominal radical hysterectomy for stage IB1 cervical cancer patients with tumor size ≤ 2 cm: a case-matched control study

Introduction to Review Articles

Toward a new stage of PD-1 blockade cancer immunotherapy

Original Article

Barriers for sperm cryopreservation in advanced germ cell tumor patients: a 20-year experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits